{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:19:27Z","timestamp":1791476367483,"version":"4.3.4"},"reference-count":2,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ORL"],"published-print":{"date-parts":[[2004]]},"abstract":"<jats:p>&lt;i&gt;Purpose:&lt;\/i&gt; To determine the effects of a standardized therapeutic protocol (short-term oral administration of prednisolone and daily intranasal spray of beclometasone) on stage I nasal polyposis over a follow-up period of 3 years. &lt;i&gt;Procedures:&lt;\/i&gt; Assessments (evaluation of nasal function and drug consumption) were conducted at baseline and every 3 months on 54 consecutive patients with stage I nasal polyposis during 3 years. &lt;i&gt;Results:&lt;\/i&gt; Over the follow-up period of 3 years, this dual modality proved to be successful in 87% of the subjects; only 13% had to undergo surgery after its failure. The average symptom reduction reached an improvement rate varying from 66 to 94.8%, according to the symptom type. The daily dosage of prednisolone and beclometasone was progressively decreased, while the gain in nasal comfort was being preserved. &lt;i&gt;Conclusion:&lt;\/i&gt; Management of stage I nasal polyps should be primarily medical.<\/jats:p>","DOI":"10.1159\/000077230","type":"journal-article","created":{"date-parts":[[2004,4,23]],"date-time":"2004-04-23T06:35:45Z","timestamp":1082702145000},"page":"27-34","source":"Crossref","is-referenced-by-count":7,"title":["Medical Treatment of Stage I Nasal Polyposis over a 3-Year Follow-Up Period"],"prefix":"10.1159","volume":"66","author":[{"given":"Pierre","family":"Bonfils","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Nor\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Avan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2004,4,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-0709(94)90056-6"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112124"}],"container-title":["ORL"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/77230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/77230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:18:57Z","timestamp":1745468337000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000077230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":2,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000077230","archive":["Portico"],"relation":{},"ISSN":["0301-1569","1423-0275"],"issn-type":[{"value":"0301-1569","type":"print"},{"value":"1423-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}